Sotorasib with panitumumab in chemotherapy-refractory KRAS^G12C-mutated colorectal cancer: a phase 1b trial.

ABSTRACT: The current third-line (and beyond) treatment options for RAS-mutant metastatic colorectal cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a KRAS (Kirsten rat sarcoma viral oncogene homolog)-G12C inhibitor, and panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, was hypothesized to overcome treatment-induced resistance. This phase 1b substudy of the CodeBreaK 101 master protocol evaluated sotorasib plus panitumumab in patients with chemotherapy-refractory KRAS^G12C-mutated metastatic colorectal cancer. Here, we report the results in a dose-exploration cohort and a dose-expansion cohort. Patients received sotorasib (960 mg, once daily) plus panitumumab (6 mg kg^-1, once every 2 weeks). The primary endpoints w

SUBMITTER: Kuboki Y 

PROVIDER: S-EPMC11135132 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature